Damora Therapeutics 1 article

The scientific profile of Damora Therapeutics combines mutant calreticulin targeting with mutCALR monoclonal antibody therapy, placing the company in targeted biologic drug development. Its therapeutic-protein platform extends through myeloproliferative neoplasm therapeutics and mutant-specific cancer antigen targeting, while megakaryocyte lineage disease biology distinguishes the binding or signaling mechanism being exploited. For Damora Therapeutics, individual protein products remain separate tags, while mutation-selective biologic therapy adds context to the broader biologics profile.